Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilongjin Tablets as Adjunct to Chemotherapy in Non-squamous NSCLC
ChiCTR-IIR-15007683Phase 4Recruiting
- Sponsor
- Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of zilongjin in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine. Primary endpoints: Total effective rate and Quality-adjusted survival time. Started Jan 2016; status: recruiting.
02
Drugs
zilongjin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-15007683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-15007683.